Frost & Sullivan study identifies top ten technologies transforming health and wellness

Provides trends, insights, and technologies of focus for stakeholders in this segment and the emerging market needs that are likely to shape R&D efforts in the near future

TechVision, Frost & Sullivan’s technology consulting division, has identified new technologies impacting the health and wellness sector. Health & Wellness Top 10 Technologies, part of the TechVision subscription, offers a detailed account of the various emerging manufacturing technologies and their impact on medical device manufacturing in the next five years.

Biosimilars, cancer screening, molecular scissors, next gen stem cells, therapeutic antibodies, 3D scaffolds, cancer immunotherapy, high throughput gene sequencing (HTGS), transdermal drug delivery and nanomedicine are the top ten areas identified by TechVision. These areas offer a number of opportunities for innovative pharma and biotech companies to deliver their product to the market.

This research service also provides trends, insights, and technologies of focus for stakeholders in this segment and the emerging market needs that are likely to shape R&D efforts in the near future.

It reports that medical device and drug manufacturing companies are entering into long-term partnerships to combine their drug delivery devices with the most active therapeutics, thereby bringing down the operational costs and saving a significant amount of time during the process. Similarly, life sciences research, cloud-based bioinformatics and nanotech-based companies are also partnering with giant pharma firms to help innovate in new customer niches and service segments, informs the research.

The global disease burden and excessive healthcare spending have resulted in numerous research and discovery programmes. Increasing application of big data analytics has led to better management of genomic data, aiding in biomarker discovery and disease understanding.

“A higher concern and commitment among the scientific and clinical communities to provide improved facilities and therapies is essential. The aging population and chronic diseases continue to exhibit a dramatic rise, spurring the demand for novel solutions in the health and wellness sector. This is driving public and private support in the funding and investment of therapeutic areas and breakthrough technologies,” said Frost & Sullivan’s TechVision industry analyst.

Early adoption of operational analytics, gene editing, 3D printing, telemedicine, cloud-based computing and advanced biosensors are poised to ramp innovation efforts to a new level. Enhanced techniques for accelerating drug discovery have improved target selection, lead identification, preclinical tests, clinical trials, chemical synthesis, formulations studies and product management.

“Precision medicine has the ability to target diseases with specialised therapies, driving promising solutions. Last-generation transdermal drug delivery technology provides patients with more accurate and precise therapeutics delivery and monitoring,” noted the analyst. “However, the rapid advancement of micro and nanotechnologies creates a confident environment among venture capitals and private investors inclined to fund precision medicine-related innovations,” he added.

EP News Bureau